Today's Rundown J&J previews $60B-a-year future with plans to go after viruses that have long evaded vaccine makers Biogen's Aduhelm 'likely' linked to Alzheimer's patient's death, RBC analyst says CVS Health plans 900 store closures, lowers guidance as retail strategy shifts digital Eli Lilly, under pressure from Biohaven, launches head-to-head migraine trial between Emgality and Nurtec Sanofi inks $270M cancer AI deal with R&D platform developer Owkin Cassava ploughs on with 2nd phase 3 trial of Alzheimer's med despite federal investigation CommonSpirit again in talks to sell off 14 North Dakota, Minnesota hospitals Where will Novartis spend the $21B from Roche stake sale? Alnylam buyout could be one: report Bristol Myers becomes latest victim of unforgiving NASH as midstage asset shelved FDA reemphasizes heart perforation risks of leadless pacemakers, with market set to grow Biden admin finalizes rule that requires insurers to submit data on drug costs, rebates Novo Nordisk bets big on RNAi, paying $3.3B to buy Dicerna Blackrock Neurotech nabs FDA breakthrough nod for system that uses thoughts to control devices Psychedelic psilocybin cuts cravings and boosts key brain functions in rat models of alcohol use disorder Personalized T cells could offer an immunotherapy option to children with brain tumors Featured Story | By Annalee Armstrong Johnson & Johnson has a lofty goal to become a $60 billion-a-year drugmaker by 2025. To reach that goal, the healthcare giant is going to take a crack at a couple of viruses that have long eluded vaccine makers. read more |
| |
|---|
|
|
| Spinal Muscular Atrophy: Overview & Outlook SMA is a rare and devastating disease. This 2-part series provides an overview of SMA and current therapies. It also provides an outlook on potential advancements that could affect the therapeutic and commercial landscapes. Download now. |
Top Stories By Fraiser Kansteiner In the aftermath of an Alzheimer's patient's death, Biogen and industry watchers have been trying to piece together the situation and determine whether the company's recently minted Alzheimer's drug should carry any blame. The answer? Probably so, one analyst says. read more By Rebecca Torrence Pharmacy and retail giant CVS Health plans to close 900 of its stores over the next three years as the company shifts its retail strategy for a new wave of digital consumers. read more By Angus Liu As Biohaven’s fast-growing Nurtec ODT pressures rival migraine prevention medicines, one injectable player decided to bring the fight to the oral drug with a head-to-head clinical trial. read more By Conor Hale The two-part deal includes a $180 million equity investment in the company alongside a $90 million discovery and development partnership that spans the next three years. read more By Kyle LaHucik Cassava Sciences is forging ahead with a second phase 3 trial of its troubled Alzheimer's drug just three days after revealing a federal investigation into the company. read more By Paige Minemyer,Dave Muoio CommonSpirit Health said it is "currently in discussions" with an unnamed third party regarding 14 hospitals and other clinics that it tried to hand off to Essentia Health earlier this year. read more By Angus Liu Novartis is getting a huge influx of cash from selling its 20-year stake in Roche, triggering speculation about where the Swiss pharma will spend the money. Another large acquisition could be next, with a familiar face now reportedly on the shopping list. read more By Annalee Armstrong Nonalcoholic fatty liver disease has claimed another victim, this time Bristol Myers Squibb is washing its hand of the midstage asset pegbelfermin. The New York Big Pharma has discontinued development of the therapy, formerly known as BMS-986036, after getting a peak at results from the phase 2b FALCON study. read more By Conor Hale With more self-contained models potentially on their way to patients, the FDA is taking steps to remind healthcare providers of certain risks posed by leadless pacemakers, including the possibility of puncturing the heart wall during implantation. read more By Paige Minemyer The Biden administration has issued an interim final rule that requires private insurers to report prescription drug costs to the federal government. read more By Nick Paul Taylor Lars Fruergaard Jørgensen has landed the major takeover he has targeted since taking over as CEO of Novo Nordisk. Having missed out on Ablynx to Sanofi in 2018, Novo Nordisk has agreed to a $3.3 billion buyout of its RNAi partner Dicerna Pharmaceuticals as part of its search for new growth drivers. read more By Andrea Park If approved by the FDA, the MoveAgain system will join an exclusive club—so exclusive, in fact, that only one other brain-computer interface has so far been cleared for commercialization. read more By Kyle LaHucik Researchers at the University of Heidelberg treated rat models of alcohol addiction with the active ingredient in magic mushrooms, psilocybin, and found that the psychedelic restored expression of a glutamate receptor called mGluR2. That reduced cravings and improved executive functioning, they found. read more By Arlene Weintraub Scientists at Children’s National Hospital identified peptides that are unique to medulloblastoma tumors and then engineered T cells so they could recognize and target those proteins. They believe the therapy could offer a personalized immuno-oncology option for children diagnosed with this common tumor type. read more | 